Recently Expired Drugs
1. Abraxane patent expiration
ABRAXANE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9101543 | BRISTOL MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(27 days ago) | |
| US7758891 | BRISTOL MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(27 days ago) | |
| US8268348 | BRISTOL MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(27 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-658) | Oct 11, 2015 |
| New Indication(I-676) | Sep 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Sep 06, 2020 |
| Orphan Drug Exclusivity(ODE-52) | Sep 06, 2020 |
| M(M-14) | Dec 06, 2022 |
| Pediatric Exclusivity(PED) | Jun 06, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of pancreatic cancer; Treatment of lung cancer
Dosage: POWDER
How can I launch a generic of ABRAXANE before its drug patent expiration?
More Information on Dosage
ABRAXANE family patents
2. Advair Hfa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7500444 | GLAXO | Actuation indicator for a dispensing device |
Feb, 2026
(22 days ago) | |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 08 June, 2006
Treatment: NA
Dosage: AEROSOL, METERED
More Information on Dosage
ADVAIR HFA family patents
3. Briviact patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6911461 | UCB | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2026
(27 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 12, 2021 |
| New Patient Population(NPP) | Aug 27, 2024 |
Drugs and Companies using BRIVARACETAM ingredient
NCE-1 date: 12 May, 2020
Market Authorisation Date: 12 May, 2016
Treatment: Treatment of partial-onset seizures in patients 4 years of age and older
Dosage: TABLET; SOLUTION
How can I launch a generic of BRIVIACT before its drug patent expiration?
More Information on Dosage
BRIVIACT family patents
4. Coreg Cr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8101209 (Pediatric) | WAYLIS | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
Mar, 2026
(9 days ago) | |
Drugs and Companies using CARVEDILOL PHOSPHATE ingredient
Market Authorisation Date: 20 October, 2006
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of COREG CR before its drug patent expiration?
More Information on Dosage
COREG CR family patents
5. Corlanor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7879842 | AMGEN | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(26 days ago) | |
| US7361650 | AMGEN | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(26 days ago) | |
| US7361649 | AMGEN | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(26 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 15, 2020 |
| Pediatric Exclusivity(PED) | Oct 22, 2026 |
| New Product(NP) | Apr 22, 2022 |
| Orphan Drug Exclusivity(ODE-234) | Apr 22, 2026 |
Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient
NCE-1 date: 16 October, 2019
Market Authorisation Date: 15 April, 2015
Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride
Dosage: TABLET
How can I launch a generic of CORLANOR before its drug patent expiration?
More Information on Dosage
CORLANOR family patents
6. Corlanor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7879842 | AMGEN | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(26 days ago) | |
| US7361649 | AMGEN | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(26 days ago) | |
| US7361650 | AMGEN | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(26 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 15, 2020 |
| Pediatric Exclusivity(PED) | Oct 22, 2026 |
| New Product(NP) | Apr 22, 2022 |
| Orphan Drug Exclusivity(ODE-234) | Apr 22, 2026 |
Drugs and Companies using IVABRADINE ingredient
NCE-1 date: 16 April, 2019
Market Authorisation Date: 22 April, 2019
Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride
Dosage: SOLUTION
More Information on Dosage
CORLANOR family patents
7. Dexilant patent expiration
DEXILANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9011926 | TAKEDA | Method for producing granules |
Feb, 2026
(24 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2012 |
| Pediatric Exclusivity(PED) | Jul 30, 2012 |
| New Patient Population(NPP) | Jul 08, 2019 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of DEXILANT before its drug patent expiration?
More Information on Dosage
DEXILANT family patents
8. Dexilant Solutab patent expiration
DEXILANT SOLUTAB's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9011926 | TAKEDA | Method for producing granules |
Feb, 2026
(24 days ago) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
More Information on Dosage
DEXILANT SOLUTAB family patents
9. Dymista patent expiration
DYMISTA's oppositions filed in EPO
DYMISTA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168620 | MYLAN | Combination of azelastine and steroids |
Feb, 2026
(24 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 01, 2015 |
| New Patient Population(NPP) | Feb 20, 2018 |
| Pediatric Exclusivity(PED) | Aug 20, 2018 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 01 May, 2012
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of DYMISTA before its drug patent expiration?
More Information on Dosage
DYMISTA family patents
10. Elepsia Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8535717 | TRIPOINT | Pharmaceutical composition |
Feb, 2026
(26 days ago) | |
| US8425938 | TRIPOINT | Pharmaceutical composition |
Feb, 2026
(26 days ago) | |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 20 December, 2018
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
ELEPSIA XR family patents
11. Flovent Hfa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7500444 | GLAXO | Actuation indicator for a dispensing device |
Feb, 2026
(22 days ago) | |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 14 May, 2004
Treatment: NA
Dosage: AEROSOL, METERED
How can I launch a generic of FLOVENT HFA before its drug patent expiration?
More Information on Dosage
FLOVENT HFA family patents
12. Jublia patent expiration
JUBLIA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214506 | BAUSCH | Method for treating onychomycosis |
Feb, 2026
(26 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 06, 2019 |
| New Patient Population(NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
NCE-1 date: 06 June, 2018
Market Authorisation Date: 06 June, 2014
Treatment: Antimycotic uses, specifically treatment of onychomycosis
Dosage: SOLUTION
How can I launch a generic of JUBLIA before its drug patent expiration?
More Information on Dosage
JUBLIA family patents
13. Koselugo patent expiration
KOSELUGO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8178693 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2026
(7 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2025 |
| ODE*(ODE*) | Apr 10, 2027 |
| Orphan Drug Exclusivity(ODE-288) | Apr 10, 2027 |
| New Product(NP) | Sep 10, 2028 |
| New Patient Population(NPP) | Nov 19, 2028 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
NCE-1 date: 10 April, 2024
Market Authorisation Date: 10 April, 2020
Treatment: NA
Dosage: CAPSULE; GRANULE
More Information on Dosage
KOSELUGO family patents
14. Mektovi patent expiration
MEKTOVI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7777050 | ARRAY BIOPHARMA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2026
(7 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
Drugs and Companies using BINIMETINIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: NA
Dosage: TABLET
How can I launch a generic of MEKTOVI before its drug patent expiration?
More Information on Dosage
MEKTOVI family patents
15. Naproxen Sodium patent expiration
NAPROXEN SODIUM's oppositions filed in EPO
NAPROXEN SODIUM IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11090280 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(17 days ago) | |
| US9693978 | BIONPHARMA | Solvent system for enhancing the solubility of pharmaceutical agents |
Mar, 2026
(17 days ago) | |
| US10022344 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(17 days ago) | |
| US10028925 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(17 days ago) | |
| US9693979 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(17 days ago) | |
Drugs and Companies using NAPROXEN SODIUM ingredient
Market Authorisation Date: 17 February, 2006
Treatment: Temporary reduction of fever
Dosage: CAPSULE
How can I launch a generic of NAPROXEN SODIUM before its drug patent expiration?
More Information on Dosage
NAPROXEN SODIUM family patents
16. Onzetra Xsail patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11571531 | CURRAX | Powder delivery devices |
Feb, 2026
(25 days ago) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: Method of drug delivery via the nasal cavity
Dosage: POWDER
More Information on Dosage
ONZETRA XSAIL family patents
17. Ozempic patent expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO NORDISK | Acylated GLP-1 compounds |
Mar, 2026
(4 hours ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
| New Dosing Schedule(D-185) | Mar 28, 2025 |
| New Indication(I-961) | Jan 28, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 06 October, 2022
Treatment: Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION
How can I launch a generic of OZEMPIC before its drug patent expiration?
More Information on Dosage
OZEMPIC family patents
18. Pradaxa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7932273 (Pediatric) | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Mar, 2026
(13 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2015 |
| New Indication(I-682) | Apr 04, 2017 |
| New Indication(I-683) | Apr 04, 2017 |
| M(M-168) | Nov 20, 2018 |
| New Strength(NS) | Nov 20, 2018 |
| New Indication(I-862) | Jun 21, 2024 |
| New Product(NP) | Jun 21, 2024 |
| Pediatric Exclusivity(PED) | Dec 21, 2024 |
Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient
Market Authorisation Date: 21 June, 2021
Treatment: NA
Dosage: PELLETS; CAPSULE
How can I launch a generic of PRADAXA before its drug patent expiration?
More Information on Dosage
PRADAXA family patents
19. Rybelsus patent expiration
RYBELSUS's oppositions filed in EPO
RYBELSUS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO NORDISK | Acylated GLP-1 compounds |
Mar, 2026
(4 hours ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| M(M-252) | Jan 16, 2023 |
| New Indication(I-976) | Oct 17, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 09 December, 2024
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET
How can I launch a generic of RYBELSUS before its drug patent expiration?
More Information on Dosage
RYBELSUS family patents
20. Tekturna patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617595 | LXO | Galenic formulations of organic compounds |
Feb, 2026
(29 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Product(NP) | Nov 14, 2020 |
| Pediatric Exclusivity(PED) | May 14, 2021 |
Drugs and Companies using ALISKIREN HEMIFUMARATE ingredient
NCE-1 date: 06 March, 2011
Market Authorisation Date: 05 March, 2007
Treatment: NA
Dosage: TABLET
How can I launch a generic of TEKTURNA before its drug patent expiration?
More Information on Dosage
TEKTURNA family patents
21. Tygacil patent expiration
TYGACIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9694078 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(7 days ago) | |
| US10588975 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(7 days ago) | |
| US9254328 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(7 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-586) | Mar 20, 2012 |
| New Indication(I-587) | Mar 20, 2012 |
| New Indication(I-588) | Mar 20, 2012 |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 15 June, 2005
Treatment: NA
Dosage: POWDER
More Information on Dosage
TYGACIL family patents
22. Valchlor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501819 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(13 days ago) | |
| US8450375 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(13 days ago) | |
| US8501818 | HELSINN | Stabilized compositions of alkylating agents and methods of using same |
Mar, 2026
(13 days ago) | |
| US7838564 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(13 days ago) | |
| US9382191 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(13 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 23, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 23, 2020 |
| Orphan Drug Exclusivity(ODE-51) | Aug 23, 2020 |
Drugs and Companies using MECHLORETHAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy
Dosage: GEL
More Information on Dosage
VALCHLOR family patents
23. Wegovy patent expiration
WEGOVY's oppositions filed in EPO
WEGOVY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO NORDISK | Acylated GLP-1 compounds |
Mar, 2026
(4 hours ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Product(NP) | Dec 22, 2028 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
| New Indication(I-973) | Aug 15, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
Market Authorisation Date: 22 December, 2025
Treatment: NA
Dosage: TABLET; SOLUTION
How can I launch a generic of WEGOVY before its drug patent expiration?
More Information on Dosage
WEGOVY family patents
24. Xifaxan patent expiration
XIFAXAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8741904 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(21 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8518949 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(21 days ago) | |
| US9271968 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(21 days ago) | |
| US10703763 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(21 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 24, 2013 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
| New Indication(I-709) | May 27, 2018 |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 25 May, 2004
Treatment: Treatment of travelers' diarrhea (td) caused by noninvasive strains of escheria coli in adult and pediatric patients 12 years of age and older; Treatment of irritable bowel syndrome with diarrhea (ibs...
Dosage: TABLET
How can I launch a generic of XIFAXAN before its drug patent expiration?
More Information on Dosage
XIFAXAN family patents